Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of patients with refractory advanced colorectal cancer.

9 Apr 2010

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

9 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company has completed enrollment of all subjects for its therapeutic cervical cancer vaccine (VGX-3100) phase I trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18, and is delivered via in vivo electroporation.

8 Apr 2010

Smoking may increase risk of MS in people who have established risk factors for MS

A new study shows that smoking may increase the risk of multiple sclerosis in people who also have specific established risk factors for MS. The research is found in the April 7, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

8 Apr 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is expressed on malignant Hodgkin lymphoma cells.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.

7 Apr 2010

Antigens of both influenza B virus strains can improve influenza vaccines

Vaccines likely would work better in protecting children from flu if they included both strains of influenza B instead of just one, Saint Louis University research has found.

7 Apr 2010

Jantibody Therapeutics, Pfenex collaborate in production of HSP-avidin fusion proteins

Boston BioCom LLC today announced the successful completion of a collaborative research agreement between its Jantibody Therapeutics LLC subsidiary and Pfenex Inc., resulting in the rapid production of a HSP-avidin fusion protein for the Jantibodies self-assembling vaccines platform.

7 Apr 2010

SRU Biosystems extends product line with the introduction of BIND SCANNER

SRU Biosystems today announced the extension of its product line of label-free instrumentation and biosensors with the introduction of its BIND® SCANNER for primary and stem cell applications. The BIND SCANNER is a first-of-its-kind, plate-based, label-free instrument capable of monitoring cellular responses at an individual cell resolution.

7 Apr 2010

Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.

6 Apr 2010

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine -targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research.

6 Apr 2010

Achievements of AFC, Abbott to be highlighted at AFC's 25th Anniversary Gala

Two events occurred in 1985 that proved pivotal in the local and national fight against AIDS: the founding of the AIDS Foundation of Chicago and the development of the first-ever diagnostic test licensed to identify HIV in the blood by Abbott.

6 Apr 2010

Emory University researchers develop experimental clinical test for XMRV

The recently discovered retrovirus, xenotropic murine leukemia virus-related virus (XMRV), has been identified in some prostate cancer patients. In light of conflicting data concerning XMRV, standardized diagnostic testing is important to identify patients in which XMRV is present and to determine whether it plays a role in the incidence of prostate cancer.

6 Apr 2010

Barrow Neurological Institute scientist receives grant to study myasthenia gravis

A scientist at Barrow Neurological Institute in Phoenix has been awarded a major grant from the Muscular Dystrophy Association to continue his groundbreaking work in the disease of myasthenia gravis.

6 Apr 2010

AnaptysBio, VLST collaborate to generate novel multi-antigen specific antibody therapeutics

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a collaboration with VLST Corporation to generate novel multi-antigen specific antibody therapeutics for the treatment of autoimmune and inflammatory disorders. This is the fourth collaboration announced by AnaptysBio during 2010.

5 Apr 2010

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine.

5 Apr 2010

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Antibody News and Research

Further Reading

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Æterna Zentaris commences perifosine Phase 3 registration trial

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Smoking may increase risk of MS in people who have established risk factors for MS

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

Antigens of both influenza B virus strains can improve influenza vaccines

Jantibody Therapeutics, Pfenex collaborate in production of HSP-avidin fusion proteins

SRU Biosystems extends product line with the introduction of BIND SCANNER

Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Achievements of AFC, Abbott to be highlighted at AFC's 25th Anniversary Gala

Emory University researchers develop experimental clinical test for XMRV

Barrow Neurological Institute scientist receives grant to study myasthenia gravis

AnaptysBio, VLST collaborate to generate novel multi-antigen specific antibody therapeutics

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo